GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » ROE %

Phibro Animal Health (Phibro Animal Health) ROE % : 1.87% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Phibro Animal Health's annualized net income for the quarter that ended in Dec. 2023 was $5.1 Mil. Phibro Animal Health's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $271.9 Mil. Therefore, Phibro Animal Health's annualized ROE % for the quarter that ended in Dec. 2023 was 1.87%.

The historical rank and industry rank for Phibro Animal Health's ROE % or its related term are showing as below:

PAHC' s ROE % Range Over the Past 10 Years
Min: 5.41   Med: 27.29   Max: 269.25
Current: 5.41

During the past 13 years, Phibro Animal Health's highest ROE % was 269.25%. The lowest was 5.41%. And the median was 27.29%.

PAHC's ROE % is ranked better than
52.7% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.385 vs PAHC: 5.41

Phibro Animal Health ROE % Historical Data

The historical data trend for Phibro Animal Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health ROE % Chart

Phibro Animal Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.29 16.60 25.49 19.63 11.97

Phibro Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.86 14.86 16.58 -11.54 1.87

Competitive Comparison of Phibro Animal Health's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phibro Animal Health's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's ROE % distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's ROE % falls into.



Phibro Animal Health ROE % Calculation

Phibro Animal Health's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=32.606/( (262.442+282.509)/ 2 )
=32.606/272.4755
=11.97 %

Phibro Animal Health's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=5.096/( (273.069+270.803)/ 2 )
=5.096/271.936
=1.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Phibro Animal Health  (NAS:PAHC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=5.096/271.936
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5.096 / 999.772)*(999.772 / 968.6155)*(968.6155 / 271.936)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.51 %*1.0322*3.5619
=ROA %*Equity Multiplier
=0.53 %*3.5619
=1.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=5.096/271.936
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (5.096 / 14.26) * (14.26 / 62.804) * (62.804 / 999.772) * (999.772 / 968.6155) * (968.6155 / 271.936)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.3574 * 0.2271 * 6.28 % * 1.0322 * 3.5619
=1.87 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Phibro Animal Health ROE % Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phibro Animal Health (Phibro Animal Health) Business Description

Traded in Other Exchanges
Address
300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Executives
Judith Weinstein officer: See Remarks C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran director
Larry Lee Miller officer: Chief Operating Officer 8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio officer: Chief Financial Officer C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman officer: President,North America Region C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim director, officer: Exec. VP, Corporate Strategy 300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras officer: Pres Animal Health & Nutr N.A. 5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim director, 10 percent owner, officer: President and CEO C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc 10 percent owner 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim director GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino officer: SEE REMARKS GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson officer: Chief Financial Officer 7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson director 2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger officer: SVP, Gen Counsel and Corp Sec 41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046